These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37528534)

  • 1. Piperine improves levodopa availability in the 6-OHDA-lesioned rat model of Parkinson's disease by suppressing gut bacterial tyrosine decarboxylase.
    Hu X; Yu L; Li Y; Li X; Zhao Y; Xiong L; Ai J; Chen Q; Wang X; Chen X; Ba Y; Wang Y; Wu X
    CNS Neurosci Ther; 2024 Feb; 30(2):e14383. PubMed ID: 37528534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
    Atlas D
    CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Piperine promotes PI3K/AKT/mTOR-mediated gut-brain autophagy to degrade α-Synuclein in Parkinson's disease rats.
    Yu L; Hu X; Xu R; Zhao Y; Xiong L; Ai J; Wang X; Chen X; Ba Y; Xing Z; Guo C; Mi S; Wu X
    J Ethnopharmacol; 2024 Mar; 322():117628. PubMed ID: 38158101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.
    Shen H; Kannari K; Yamato H; Arai A; Matsunaga M
    Tohoku J Exp Med; 2003 Mar; 199(3):149-59. PubMed ID: 12703659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Shin KS; Choi HS; Zhao TT; Suh KH; Kwon IH; Choi SO; Lee MK
    Arch Pharm Res; 2013 Jun; 36(6):759-67. PubMed ID: 23539311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
    Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
    Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson's disease by regulating gut microbiota.
    Wang Y; Tong Q; Ma SR; Zhao ZX; Pan LB; Cong L; Han P; Peng R; Yu H; Lin Y; Gao TL; Shou JW; Li XY; Zhang XF; Zhang ZW; Fu J; Wen BY; Yu JB; Cao X; Jiang JD
    Signal Transduct Target Ther; 2021 Feb; 6(1):77. PubMed ID: 33623004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease.
    Zhang X; Andren PE; Chergui K; Svenningsson P
    Neuropharmacology; 2008 Jun; 54(7):1143-52. PubMed ID: 18423776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
    El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
    Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-DOPA modulation of corpus striatal dopamine and dihydroxyphenylacetic acid output from intact and 6-OHDA lesioned rats.
    Xu K; Dluzen DE
    J Neural Transm (Vienna); 1996; 103(11):1295-305. PubMed ID: 9013416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.
    Malmlöf T; Feltmann K; Konradsson-Geuken Å; Schneider F; Alken RG; Svensson TH; Schilström B
    J Neural Transm (Vienna); 2015 Feb; 122(2):259-72. PubMed ID: 24906468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
    Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
    Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson's disease.
    Kamińska K; Lenda T; Konieczny J; Lorenc-Koci E
    Psychopharmacology (Berl); 2022 Nov; 239(11):3633-3656. PubMed ID: 36178508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of presynaptic corticostriatal glutamate activity attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's disease mice.
    Huang YT; Chen YW; Lin TY; Chen JC
    Neurobiol Dis; 2024 Apr; 193():106452. PubMed ID: 38401650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism.
    Maini Rekdal V; Bess EN; Bisanz JE; Turnbaugh PJ; Balskus EP
    Science; 2019 Jun; 364(6445):. PubMed ID: 31196984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake.
    Chotibut T; Apple DM; Jefferis R; Salvatore MF
    PLoS One; 2012; 7(12):e52322. PubMed ID: 23300642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal Form of L-Dopa and SH-Sy5y Cell-Derived Exosomes Modulate the Tyrosine Hydroxylase/Dopamine Receptor D2 Signaling Pathway in Parkinson's Rat Models.
    Zarrin P; Dehghani Ashkezari M; Seifati SM
    J Mol Neurosci; 2021 Dec; 71(12):2583-2592. PubMed ID: 34125397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
    Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
    Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.